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Novelty and Impact 
Circulating insulin-like growth factors (IGF) and their binding proteins (IGFBP) have 
been associated with prostate cancer risk in observational epidemiological studies but it 
is not clear whether there is a causal relationship between IGF and IGFBP levels and 
disease. We used Mendelian randomization in an attempt to determine whether there is 
a causal effect of IGF and IGFBP levels on prostate cancer risk, progression and mortality.  
Our genetic approach provides evidence of the involvement of the IGF axis in prostate 
cancer.  
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Abstract 
Circulating insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) are 
associated with prostate cancer. Using genetic variants as instruments for IGF peptides, 
we investigated whether these associations are likely to be causal.  
We identified from the literature 56 single nucleotide polymorphisms (SNPs) in the IGF 
axis previously associated with biomarker levels (8 from a genome-wide association 
study [GWAS] and 48 in reported candidate genes).  In ~700 men without prostate cancer 
and two replication cohorts (N~900 and ~9,000), we examined the properties of these 
SNPS as instrumental variables (IVs) for IGF-I, IGF-II, IGFBP-2 and IGFBP-3. Those 
confirmed as strong IVs were tested for association with prostate cancer risk, low (< 7) 
vs high (≥ 7) Gleason grade, localised vs advanced stage, and mortality, in 22,936 controls 
and 22,992 cases. IV analysis was used in an attempt to estimate the causal effect of 
circulating IGF peptides on prostate cancer. 
Published SNPs in the IGFBP1/IGFBP3 gene region, particularly rs11977526, were strong 
instruments for IGF-II and IGFBP-3, less so for IGF-I. Rs11977526 was associated with 
high (vs low) Gleason grade (OR per IGF-II/IGFBP-3 level-raising allele 1.05; 95% CI 1.00, 
1.10). Using rs11977526 as an IV we estimated the causal effect of a one SD increase in 
IGF-II (~265 ng/ml) on risk of high vs low grade disease as 1.14 (95% CI 1.00, 1.31).  
Because of the potential for pleiotropy of the genetic instruments, these findings can only 
causally implicate the IGF pathway in general, not any one specific biomarker.  
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Introduction 
Prostate cancer is the most common male cancer in industrialised countries, yet there are 
no established, potentially modifiable risk factors for prevention1. The nutritionally-
regulated insulin-like growth factors (IGFs), and their modulating binding proteins 
(IGFBPs) play a key role in somatic growth, and activate carcinogenic intracellular 
signalling networks1. Meta-analyses of epidemiological studies generally observe 
positive associations of circulating IGF-I with prostate cancer2–4, but substantial 
differences exist between studies5,6. 
Such diverse evidence indicates that causation remains to be established. Alternative 
explanations for the observed association of IGF-axis peptides with prostate cancer 
include: reverse causality, because tumours may promote an endocrine response7; 
confounding by dietary8, nutritional9 and lifestyle10 factors; measurement error11, as 
single serum measurements may inadequately reflect long-term exposure; or detection 
bias11, occurring, for example, if IGF-I causes symptomatic benign prostatic hyperplasia 
(BPH) that results in the serendipitous finding of latent cancer on diagnostic biopsy.  
Mendelian randomization (MR)12 seeks to establish causality by using genetic variants as 
proxies for the exposure of interest. Since alleles randomly assort at gamete formation 
and segregate randomly at conception to generate genotypes, associations between 
genotypes and outcome are not generally confounded by behavioural or environmental 
factors and cannot be explained by reverse causation. Genetic variation may also be a 
better measure of exposure over a lifetime than a single serum measurement, as those 
with genotypes causing high (or low) IGF levels will have been, in effect, randomly 
allocated to high (or low) IGF levels from birth.  To determine causality, MR relies on an 
association between genetic variant (also known as instrument) and exposure so that the 
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greater the correlation between the two, and thus the more variation in the exposure 
phenotype explained by the genotype, the more reliable the causal inference. 
Additionally, the instrument is expected to influence the outcome only via the exposure 
(i.e. absence of horizontal pleiotropy13) and to be independent from confounders of the 
relationship between exposure and outcome. 
We used an MR approach in an attempt to assess the causal role of the IGF axis in prostate 
cancer.  First, we validated genetic variants previously associated with IGF levels in the 
literature to confirm reported associations of the SNPs (especially SNPs selected from 
candidate gene studies), and to assess the potential for pleiotropic effects of the genetic 
variants on more than one IGF protein. Second, we performed a large case-control study 
based on an international prostate cancer consortium of >22,000 case/control pairs 
using the validated polymorphisms.   
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Materials and Methods 
Study populations 
ProtecT (Prostate testing for cancer and Treatment) study 
The association of genetic variants with IGF levels was evaluated in the control arm of a 
case–control study nested within ProtecT, a UK multicentre study to identify localised 
prostate cancer and evaluate its management in a randomly allocated controlled trial5.  
All men without evidence of prostate cancer were eligible for selection as controls; that 
is, men with a prostate specific antigen (PSA) test < 3 ng/ml, or men with a raised PSA (≥ 
3 ng/ml) combined with at least one negative diagnostic biopsy. Of the 2,766 controls 
who underwent measures of IGFs in ProtecT5, ~700 men also had genome-wide genotype 
data available (mean age ± SD: 62.1 ± 5.0 years).  
Blood samples for IGF measurement in ProtecT were drawn at the time of the PSA test, 
frozen at -80˚C within 36 hours, then transferred on dry ice for assay4.  Total IGF-I, IGF-II 
and IGFBP-3 levels were measured by in-house radioimmunoassay (RIA) and circulating 
IGFBP-2 was measured using a one-step sandwich ELISA (DSL-10-7100; Diagnostic 
Systems Laboratories). The intra-class correlations (ICC) for within-assay variability for 
IGF-I, IGF-II, IGFBP-2 and IGFBP-3 were 0.86, 0.91, 0.95 and 0.88; the ICCs for between-
assay variability were 0.66, 0.84, 0.81 and 0.71, respectively. 
Genome-wide genotyping of participants was carried out at the Centre National de 
Génotypage (CNG, Evry, France), using the Illumina Human660W-Quad_v1_A array 
(Illumina Inc., San Diego, CA). The quality control process performed before imputation 
excluded individuals on the basis of the following: sex mismatches, minimal (< 0.325) or 
excessive (> 0.345) heterozygosity, disproportionate levels of individual missingness (> 
3%), cryptic relatedness measured as a proportion of identity by descent (IBD > 0.1), and 
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insufficient sample replication (IBD < 0.8). All individuals with non-European ancestry, 
and SNPs with a minor allele frequency (MAF) below 1%, a call rate of < 95% or out of 
Hardy-Weinberg equilibrium (p < 5x10-7) were removed. Autosomal genotypic data were 
imputed using Markov Chain Haplotyping software (MACH v.1.0.16)14 and phased 
haplotype data from European (CEU) individuals (HapMap release 22, Phase II NCBI B36, 
dbSNP 126) based on 514,432 autosomal SNPs. After imputation, all SNPs with indication 
of poor imputation quality (r2 hat < 0.3) were eliminated. The working dataset consisted 
of 2,927 individuals (1,136 cases, 1,791 controls) of European ancestry. 
Trent Multicenter Research Ethics Committee (MREC) approved both the ProtecT study 
(MREC/01/4/025), and the associated ProMPT study which collected biological material 
(MREC/01/4/061).  Written informed consent was obtained from all men. 
 
ALSPAC (Avon Longitudinal Study of Parents and Children) 
We used ALSPAC to replicate ProtecT findings. ALSPAC is a population-based prospective 
cohort study of children and their parents. The study is described in detail elsewhere15–
17 (http://www.bristol.ac.uk/alspac/). Measurement of circulating IGF-I, IGF-II and 
IGFBP-3 in plasma or serum was carried out as in ProtecT. IGFBP-2 was not measured. 
The intra- and inter-assay coefficients of variation (CV) were 7.0 and 14.3% for IGF- I, 7.9 
and 18.6% for IGF-II, and 6.1 and 8.7% for IGFBP-318.   
GWAS data for the children were generated by Sample Logistics and Genotyping Facilities 
at the Wellcome Trust Sanger Institute (Cambridge, UK) and the Laboratory Corporation 
of America (Burlington, NC, USA) with support from 23andMe (Mountain View, CA, USA) 
using the Illumina HumanHap550 quad chip. The mothers were genotyped at CNG using 
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the Illumina Human660W quad array. All individuals of non-European ancestry, 
ambiguous sex, extreme heterozygosity, cryptic relatedness (IBD > 0.1 in children, > 
0.125 in mothers), high missingness (> 3% in children, > 5% in mothers) and insufficient 
sample replication (IBD < 0.8) were removed. SNPs with genotyping rate < 95%, MAF < 
1%, or out of Hardy-Weinberg equilibrium (p < 5x10-7 in children, p < 1x10-6 in mothers) 
were excluded. Genotypic data was subsequently phased with ShapeIT v2.r64419, and 
imputed using IMPUTE v2.2.220 and phased haplotype data from the 1000 Genomes 
reference panel (phase 1, version 3), based on 465,740 SNPs. The cleaned dataset 
consisted of 8,237 children and 8,196 mothers. Up to ~400 pregnant women (mean ± SD 
age at delivery: 28.7 ± 5.4 years) and ~450 children at different ages (mean ± SD age: 61.8 
± 0.8 months, 54% male; 7.5 ± 0.2 years, 54% male; 8.2 ± 0.1 years, 56% male), as well as 
~500 umbilical cord samples had genotypes and IGF measures for analysis. 
Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee 
and the Local Research Ethics Committees 
(http://www.bristol.ac.uk/alspac/researchers/data-access/ethics/lrec-
approvals/#d.en.164120). Written informed consent was obtained from all participants 
in the study.  
 
Understanding Society: the UK Household Longitudinal Study (UKHLS) 
SNPs validated in ProtecT were also examined in the UKHLS study, which is a stratified 
clustered random sample of households, representative of the UK population 
(https://www.understandingsociety.ac.uk/). Serum IGF-I levels were measured using an 
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electrochemiluminescent immunoassay on an IDS ISYS analyser. The inter- and intra-
assay CVs were < 14%. No measurements of IGF-II, IGFBP-2 or IGFBP-3 were available. 
In total, 10,480 samples were genotyped on the Illumina HumanCoreExome chip (v1.0) 
at the Wellcome Trust Sanger Institute. Data quality control (QC) was performed at the 
sample-level using the following filters: call rate < 98%, autosomal heterozygosity 
outliers (> 3 SD), gender mismatches, duplicates as established by IBD analysis (PI_HAT 
> 0.9), ethnic outliers. Variants with a Hardy-Weinberg equilibrium p-value < 10-4, a call 
rate below 98% and poor genotype clustering values (< 0.4) were removed, as well as 
mitochondrial polymorphisms, leaving 518,542 variants. Imputation was performed at 
the UCL Genetics Institute using Minimac version 5-29-1221, MaCH14 for phasing, and the 
1000 Genomes Project, March 2012, version 3, NCBI build GRCh37/hg19 as a reference 
sample. The final sample consisted of 9,944 individuals. As UKHLS is a household study 
we additionally eliminated individuals who were related (> 5%), thus the working sample 
included 9,237 participants (mean ± SD age: 54.1 ± 16.1 years, 44% male). 
UKHLS is designed and conducted in accordance with the ESRC Research Ethics 
Framework and the ISER Code of Ethics. The University of Essex Ethics Committee 
approved waves 1–5 of UKHLS. Approval from the National Research Ethics Service was 
obtained for the collection of biosocial data by trained nurses in waves 2 and 3 of the 
main survey (Oxfordshire A REC, Reference: 10/H0604/2). 
 
PRACTICAL Consortium (PRostate cancer AssoCiation group To Investigate Cancer-
Associated aLterations in the genome) 
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We investigated associations of published IGF-related genetic variants, evaluated as 
instruments in ProtecT and replicated in ALSPAC and/or UKHLS, with prostate cancer 
risk, progression and mortality in men from 25 studies contributing to the international 
PRACTICAL consortium22 (http://practical.ccge.medschl.cam.ac.uk).  Seventeen studies 
were from Europe, six from North America and two from Australia, and comprised 
population samples of predominantly European ancestry22 (Table 1). Data on cancer 
stage, grade and method of diagnosis were collected by each study using a variety of 
methods. We categorised cancers as localised (T1 or T2 on TNM staging, or if not 
available, “localised” on SEER staging) or advanced (T3 or T4, or “regional” or “distant” 
on SEER staging).   
Genotyping of PRACTICAL samples was carried out using an Illumina Custom Infinium 
genotyping array (iCOGS), designed for the Collaborative Oncological Gene-Environment 
Study (COGS) (http://www.cogseu.org/) and consisting of 211,155 SNPs22. This array 
was devised to evaluate associations of genetic variants with breast, ovarian and prostate 
cancer (85,278 were specifically chosen for their potential relevance to prostate cancer). 
A total of 201,598 SNPs passed QC for the European ancestry samples22. Imputation of 
~17 million SNPs/indels using the 1000 Genomes Project (version 3, March 2012 
release) as a reference panel was performed with the program IMPUTE v.220. 
Polymorphisms with quality information scores of (r2) > 0.3 and MAF > 0.5% were taken 
forward for analysis23. Overall there were 22,992 prostate cancer cases and 22,936 
controls with genotype data available. 
All studies have the relevant Institutional Review Board approval in each country in 
accordance with the Declaration of Helsinki. 
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Identification of genetic variants associated with IGF levels in the literature 
We selected single nucleotide polymorphisms (SNPs) associated with circulating IGF 
levels from the National Human Genome Research Institute-European Bioinformatics 
Institute (NHGRI-EBI) catalog of genome-wide association studies (GWAS) 
(https://www.ebi.ac.uk/gwas/) and by conducting a PubMed literature search. All SNPs 
chosen were associated with IGF concentration at the significance thresholds established 
by each study (p < 5x10-7 in the discovery GWAS; usually p < 0.05 in candidate gene 
studies). 
 
Validation of genetic variants as instruments of IGF levels  
The properties of the SNPs as instrumental variables (IV) were assessed in ProtecT 
controls by examination of: i) F statistics (with values lower than 10 taken as evidence of 
a weak instrument24) and R2 values (the proportion of variation in IGF levels explained 
by the genetic variant) from the linear regression of each biomarker on the SNP; ii) 
associations of the genetic variants with potential confounding factors and other 
variables (age, PSA at recruitment, body mass index (BMI), height, leg-length, BPH and 
diabetes); and iii) possible pleiotropic effects of the variants on more than one IGF 
peptide25. The validated genetic instruments were tested for replication in ALSPAC 
mothers and children, and UKHLS participants.  
 
Statistical Analysis 
All SNPs were examined for deviation from Hardy-Weinberg equilibrium using the hwsnp 
function in the statistical package Stata. Linear and logistic regression were used as 
appropriate to investigate the effect of SNPs on IGF-I, IGF-II, IGFBP-2, IGFBP-3, PSA and 
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potential confounders. For the validated SNPs we ran meta-analyses across all 
PRACTICAL studies to evaluate between-study heterogeneity in the association with 
prostate cancer risk, Gleason grade (low: <7 vs high: ≥ 7) and stage (localised vs 
advanced). We computed pooled ORs assuming a fixed-effects model when there was no 
evidence of heterogeneity (p > 0.05), otherwise we used a random-effects model. Logistic 
regression with robust standard errors, to account for within-study clustering, was 
performed to test for associations of all polymorphisms across the IGFBP1/IGFBP3 region 
and SNPs in other chromosomal regions with the above prostate cancer outcomes.  
 
Linkage disequilibrium (LD) between pairs of variants in the IGFBP-1/IGFBP-3 gene 
region was calculated with the program LDlink using data for the GBR population 
(English and Scottish) in Phase 3 of the 1000 Genomes Project26. r2 values obtained with 
LDlink were then used to create an LD plot of the region with the R package LDheatmap 
(http://www.R-project.org). Functional consequences of genetic polymorphisms were 
predicted using SNPnexus (http://www.snp-nexus.org/). 
 
Survival analysis 
Amongst men with prostate cancer, we estimated associations of the validated SNPs with 
long term (15-year) survival, examining all-cause and prostate cancer-specific mortality 
using Cox proportional hazards regression with date at diagnosis as the start date and 
date at death or final follow-up time-point as the exit date, with robust standard errors 
to account for within-study clustering. 
 
Instrumental variable (IV) analysis 
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To estimate the causal effect of IGF levels on prostate cancer, we used validated SNPs as 
the instruments in a two-sample ratio estimator IV analysis27,28 (Figure 1). The ratio 
represents the causal log odds ratio of a one unit increase in circulating IGF on the risk of 
prostate cancer. IV analysis was conducted for the SNPs showing the strongest 
association with prostate cancer, which were also associated with circulating IGFs in 
ProtecT, ALSPAC or UKHLS, and the estimates are given per standard deviation (SD) 
increase in IGF levels. 
 
Adjustments 
Principal components reflecting each population’s genetic structure were included as 
covariates in the regression models to account for confounding by population 
stratification. Additional adjustments for age at diagnosis, age at blood sample collection, 
gestational age and sex were made when appropriate. 
 
Unless otherwise specified, all analyses were carried out in Stata version 13 (StataCorp 
LP, 2013, College Station, TX). 
 
Results 
We identified 56 SNPs that were associated with circulating IGF peptides in GWAS (n=8) 
or candidate gene studies (n=48) (Supplementary Table 1). Most of these SNPs were 
located in the IGF1 and IGFBP1/IGFBP3 gene regions on chromosomes 12q23.2 and 
7p12.3, respectively, and showed associations with IGF-I and IGFBP-3 levels. We could 
only find one candidate gene study that had examined the relationship of blood IGF-II 
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with genetic polymorphisms29, and one that had similarly considered IGFBP-2 
concentrations30. 
 
Validation of the association of published SNPs with IGF levels in ProtecT controls 
IGF-I, IGF-II and IGFBP-3 blood concentrations were approximately normally distributed, 
as opposed to IGFBP-2, which was natural log-transformed for analysis. Mean (± SD) 
levels are given in Supplementary Table 2.  All SNPs, with the exception of rs3770473 
(p < 0.0001), conformed with Hardy-Weinberg equilibrium. Six SNPs in the 
IGFBP1/IGFBP3 gene region were strongly associated with circulating IGFs (F-statistic > 
10)31, individually explaining ~2 – 5% of variation in biomarker concentration (Table 2). 
The genetic variant showing the strongest association, and thus ranking as the best 
instrument, was rs11977526 (F = 38, R2 = 5%), the lead SNP in a GWAS of IGF-I and 
IGFBP-3 levels32. Five out of the six SNPs (including rs11977526) were not associated 
with the IGF biomarker reported in the literature but with IGF-II instead. Only one SNP 
(rs700752) was consistent with published reports, showing associations with both IGF-I 
and IGFBP-3 (although it qualified as a strong instrument only for IGFBP-3) (Table 2). 
Three of the most robustly associated variants (rs11977526, rs1496499, rs700752) had 
been identified in a GWAS including over 10,000 participants32, and the remaining three 
(rs3110697, rs2132571, rs924140) were in strong LD with the first two 
(Supplementary Figure 1).  
Other SNPs identified in the same GWAS, but located in different chromosomal regions, 
were either not associated with the serum concentration of any biomarker (rs4234798, 
rs7780564 and rs1245541), marginally associated with a biomarker other than the one 
reported in the GWAS (rs2153960 with IGFBP-2 instead of IGF-I), or showed an 
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association with the GWAS-reported biomarker (IGFBP-3) but did not satisfy the 
requirements of a strong instrument (rs1065656) (Table 2). 
The validated SNPs were not correlated with potential confounders or PSA, after applying 
a Bonferroni correction for multiple testing (p-value > 0.001) (Supplementary Table 3). 
 
Replication in ALSPAC 
Mean (± SD) levels of IGF-I, IGF-II, and IGFBP-3 for mothers and children are shown in 
Supplementary Table 2. All SNPs that were strong instruments for IGF-II in ProtecT 
(rs11977526, rs1496499, rs2132571, rs3110697, rs924140) plus two extensively 
studied functional variants rs2854744 (-202 A/C) and rs2854746 (Gly32Ala) that were 
not genotyped or imputed in ProtecT and are in strong LD with rs11977526 (r2 = 0.66 for 
rs2854744 and 0.98 for rs2854746 in the UK population), were replicated with respect 
to IGF-II levels in ALSPAC. The strongest instruments were: rs2854746, explaining 
between 2.5% (in cord blood samples) and 11.4% (in 61 month-old children) of variation 
in IGF-II; and rs11977526, explaining 4.3% of variation in maternal IGF-II. Unlike in 
ProtecT, and in agreement with the literature, these SNPs were generally also associated 
with IGFBP-3 levels, although not as strongly as with IGF-II. The strongest instruments 
for IGFBP-3 were rs2854746 (R2 = 4.9% in mothers), rs1496499 (R2 = 6.1% in children) 
and rs700752 (R2 = 4.1% in children) (Supplementary Table 4). No strong associations 
with IGF-I were uncovered. SNPs identified in the discovery GWAS, not on 7p12.3, were 
weakly or not at all (rs7780564) associated with IGF levels (Supplementary Table 5). 
 
Replication in UKHLS 
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Mean (± SD) IGF-I concentrations for men and women who participated in UKHLS are 
shown in Supplementary Table 2, whilst association results are displayed in 
Supplementary Table 4. All SNPs, with the exception of rs2132571, were associated 
with serum IGF-I. SNPs that were in strong LD (i.e. all excluding rs700752) showed 
associations consistent with those reported in the literature, although in the literature 
their effects were adjusted for IGFBP-3 levels, which we could not do in UKHLS as 
circulating IGFBP-3 was not available. Variants rs700752, rs11977526 and rs2854746 
qualified as strong instruments for IGF-I levels (F > 10) but did not appear to explain 
much of the variance in the trait. Results for other GWAS-identified variants can be found 
in Supplementary Table 5.  
 
Association of validated SNPs with prostate cancer risk and progression in 
PRACTICAL 
Fixed-effects and random-effects meta-analyses of the eight validated polymorphisms 
identified stronger associations with prostate cancer grade than with risk or disease 
stage (Table 3). Rs11977526 (the strongest instrument) was associated with high 
Gleason grade (OR per A allele 1.05; 95% CI 1.00, 1.10) (Supplementary Figure 2). This 
variant’s A (minor) allele was associated with increased IGF-II levels in ProtecT and 
ALSPAC, IGFBP-3 levels in the literature and ALSPAC, and with reduced IGF-I levels in 
UKHLS. Other SNPs in the region in LD with rs11977526 had a similar effect on disease 
grade (Table 3). The major allele in rs700752, which is associated with higher IGF-I 
levels, showed a weakly protective effect with respect to high grade prostate cancer (OR 
per G allele 0.97; 95% CI 0.92, 1.01) (Supplementary Figure 3). Evidence of association 
is limited when a Bonferroni correction for multiple testing is applied. 
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Survival analysis in PRACTICAL 
Rs700752 was associated with prostate cancer-specific mortality, with the allele that 
increases IGF-I and IGFBP-3 levels (major) being associated with a lower risk of death. 
No other associations with all-cause or prostate cancer-specific mortality were observed, 
except when considering the non-additive relationship of the genetic variant with 
survival (Supplementary Table 6). In the case of SNPs linked to rs11977526 (i.e. 
rs1496499, rs2854744, rs2854746 and rs924140) heterozygotes exhibited the highest 
mortality rates, compared to homozygotes. The proportional hazards assumption was 
not fulfilled for many of the variants (p < 0.05).  
 
Instrumental variable analysis 
An IV analysis using individual-level data was run for rs11977526 and IGF-II, as it had 
been genotyped/imputed in both ProtecT and PRACTICAL, and showed associations with 
circulating IGF-II in ProtecT and prostate cancer grade in PRACTICAL. The estimated 
causal OR per one SD (~265 ng/ml) increase in serum IGF-II was 1.14 (95% CI 1.00, 1.31) 
for high (vs low) grade disease. Similarly, using information from UKHLS on the 
association between rs11977526 and IGF-I, we estimated a causal OR of 0.39 (95% CI 
0.14, 1.10) per one SD (~50 ng/ml) increase in circulating IGF-I for high Gleason grade 
cancer. 
 
We used summary data for the association of rs11977526 with IGFBP-3 from the 
discovery GWAS32 (results from the Framingham Heart Study cohort as the largest study) 
and its association with Gleason grade in PRACTICAL, to estimate the causal OR per one 
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SD (~1000 ng/ml) increase in IGFBP-3 as 1.15 (95% CI 1.00, 1.32) for high (vs low) grade 
disease.  
 
Finally, if rs700752 is employed as an IV for serum IGF-I and IGFBP-3, based on ProtecT 
findings, the causal estimates regarding prostate cancer-specific mortality were HR 0.72 
(95% CI 0.53, 0.98) per SD increase in IGF-I, and HR 0.76 (95% CI 0.60, 0.95) per SD 
increase in IGFBP-3. Considering UKHLS as the source of the SNP-exposure effect, the 
causal estimate per SD increase in IGF-I levels was lower but comparable, HR 0.47 (95% 
CI 0.29, 0.82). 
 
Further analysis (see Supplementary Results) 
In order to obtain a more complete picture of the IGFBP1/IGFBP3 genetic region and its 
relationship to prostate cancer, we carried out an analysis of all additional SNPs within 
these genes that were available in PRACTICAL (n=39).  
We also examined the association of non-validated SNPs from the discovery GWAS with 
prostate cancer risk, progression and mortality. 
 
Discussion 
We found that variants that had been identified in a GWAS32 and others linked to them, 
were the strongest instruments for the exposures examined, as expected. Surprisingly, in 
ProtecT most of these variants were strong instruments for a related exposure (i.e. IGF-
II) and not for the exposure for which they were originally described (i.e. IGF-I and IGFBP-
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3). The discovery GWAS did not analyse IGF-II or other IGBP proteins besides IGFBP-3, 
which the authors considered a limitation of their study. Additionally, all the variants that 
proved to be strong instruments for serum IGFs were located on chromosome 7p12.3 in 
the IGFBP1/IGFBP3 gene region. This is consistent with the dominant effect of IGFBP-3 
on circulating IGF levels. The IGFs are not stored in any tissue but are constitutively 
secreted from most tissues and stored in a circulating reservoir by forming a ternary 
complex with IGFBP-3 and an acid labile subunit that extends the circulating half-life of 
IGFs from 8-12 minutes to 15-18 hours33.  
To investigate the discrepancy between our findings in ProtecT and the literature reports, 
we ran an analysis of SNPs confirmed as strong instruments in ProtecT, in ALSPAC 
mothers (N~400) and children (N~160-450) who had IGF-I, IGF-II and IGFBP-3 
measured, and in ~9,000 men and women from the UKHLS with measures of circulating 
IGF-I. Robust associations of IGFBP1/IGFBP-3 SNPs with IGF-II as well as with IGFBP-3 
levels were identified in pregnant women and in children across several ages. None of the 
SNPs were associated with IGF-I in ALSPAC. However, in UKHLS the majority of these 
variants showed an association with IGF-I concentration, the most convincing being 
rs700752. 
The remaining GWAS-identified IGF-associated variants on chromosomes 4p16.1, 6q21, 
7p21.3, 10q22.1 and 16p13.3 were not strong instruments in ProtecT, ALSPAC or UKHLS. 
When examined in relation to prostate cancer, the validated IGF instruments showed 
weak associations with Gleason grade. The strongest instrument in the literature and in 
ProtecT, rs11977526, and other SNPs in LD with it were associated with high (vs low) 
grade disease. In addition, a few of the strong instruments validated in this study were 
associated with all-cause mortality under a non-additive genetic model (on the basis on 
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an earlier report of non-additivity in the relationship of rs11977526 and longevity34). On 
the other hand, rs700752 exhibited the strongest association with prostate cancer-
specific mortality under an additive model. 
The non-validated instruments from the discovery GWAS32 did not show an association 
with any prostate cancer outcome, except for rs2153960, which was associated with 
aggressiveness and mortality. This SNP lies in the FOXO3 gene, well-known for its 
relationship with longevity35, and it is possible that this is driving the association with 
cancer. 
A deeper look into the IGFBP1/IGFBP3 region revealed at least two independent signals 
of association with prostate cancer following the regional LD structure (excluding 
rs700752): one towards the IGFBP1 gene, and one encompassing the IGFBP3 gene. The 
lack of –or marginal- association with IGF-I, IGF-II and IGFBP-3 levels of SNPs in or near 
IGFBP1 may mean that these variants are predominantly influencing IGFBP-1 levels. 
Recently higher circulating IGFBP-1 was found to be associated with lower prostate 
cancer risk4,36. It is also conceivable that these signals may all be linked to another, causal 
signal in the region.  
An MR analysis using rs11977526 as the IV, revealed that a large increase in the 
concentration of IGF-II or IGFBP-3 (~1 SD) would increase the likelihood of progression 
to high grade cancer by approximately 15%, whilst a similar increase in IGF-I levels 
would be protective against disease progression. Conversely, if rs700752 (a SNP not in 
LD with, and quite distant from rs11977526) is used as an instrument for IGF levels, a 
one SD increase in IGF-I or IGFBP-3 would reduce the risk of prostate cancer-specific 
mortality between ~25% and 50%, depending on the genotype-exposure estimates 
considered. Given the association of each SNP with multiple IGF biomarkers the estimates 
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obtained using different sets of instruments and exposures could provide fairly different 
answers. 
In summary, we have confirmed the association of genetic variants that lie towards the 
IGFBP3 end of the IGFBP1/IGFBP3 region with IGFBP-3 and IGF-I levels, and we have 
discovered a novel association of some of the same variants with circulating IGF-II, which 
was observed in both ProtecT and ALSPAC. The differences found in the associations of 
the polymorphisms with the biomarkers could relate to the cohort composition (for 
instance, differing age structure or sex proportion), the method of assaying blood 
concentrations (e.g. physical vs chemical dissociation of IGF-I from IGFBPs used in 
ProtecT/ALSPAC and UKHLS, respectively) or to having reduced statistical power to 
detect them, as ProtecT and ALSPAC had low numbers of participants with IGF measures.  
Our findings have important implications for MR as the SNPs examined have pleiotropic 
effects on IGF peptides and it will not be possible to isolate the effect of any one biomarker 
on an outcome of interest using these instruments. Nevertheless, these variants could be 
used as strong instruments for the more general causal involvement of the IGF axis on a 
particular trait or disease, which undoubtedly provides valuable information regarding 
the mechanisms leading to the onset and progression of the condition. Because of the 
regional pattern of LD and the lack of data on low frequency variants in IGFBP1/IGFBP3 
it has not been possible to fully identify the functional polymorphisms responsible for 
variation in IGF levels, which could have helped better define the instruments for MR. In 
the future a GWAS on circulating IGFBP-1 might provide useful instruments for this 
exposure as well. 
We have also detected associations of SNPs in IGFBP-1/IGBP-3 with prostate cancer 
aggressiveness which suggest a positive relationship with higher circulating IGF-II and 
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possibly IGFBP-3 (this varies depending on the instrument used). On the other hand, 
results obtained with instruments rs11977526 and rs700752 independently indicate an 
inverse association of IGF-I levels with Gleason grade and mortality. Although these 
associations were not very strong it is likely that local IGF levels in the prostate may be 
more prominent and there may be other determinants of such local levels. It is important 
to replicate of our findings in a non-overlapping prostate cancer set or using stronger 
instruments when they become available. Additionally, the association with mortality 
deserves further scrutiny including a more thorough assessment of the underlying 
genetic model.  
 
Comparison with existing literature on IGF and prostate cancer 
Prior studies that have examined the relationship between genetic variants in IGF 
pathway genes (primarily IGF1 and IGFBP3) and prostate cancer, some of which also 
analysed circulating IGF proteins, reported for the most part an association of IGF1 
genetic polymorphisms with disease in Europeans, African Americans, Japanese and 
Chinese37–42. Two studies, carried out in African American and Korean men, respectively, 
showed an association of the IGFBP3 SNP rs2854744 with IGFBP-3 levels and prostate 
cancer risk43,44. Among the studies conducted in European populations that measured 
circulating IGF-I and IGFBP-3, some found an association of the SNPs with serum levels 
but not with prostate cancer, and of serum levels with prostate cancer37,45,46. Some did 
not find an association of the SNPs with serum levels, although both the SNPs and the 
serum levels were associated with prostate cancer37,39, and one identified an association 
of the genetic variants with serum levels but no association of variants or levels with 
prostate cancer39.   
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Compared to these studies (with samples sizes ranging from 130 to ~6,000 patients and 
an equivalent number of controls), our study had good power, from a large sample size 
in PRACTICAL, to accurately estimate the genotype-outcome associations, and obtain 
precise causal odds ratios47. 
A number of observational studies have consistently reported positive associations of 
circulating IGF-I with prostate cancer, but inferences of causality are limited with 
observational studies3,4,36. MR is designed to overcome these problems if the exposure is 
adequately instrumented. Our MR estimates with independent instruments rs11977526 
and rs700752 seem to contradict observational studies on the effect of IGF-I on prostate 
cancer; however replication with, ideally, non-pleiotropic instruments is necessary. 
Observational findings for IGFBP-3 have been inconsistent3,5,6, whereas IGF-II and IGFBP-
2 have been investigated less frequently3,4. Regarding IGFBP-3, results based on the 
strongest instrument (rs11977526) are concordant with the positive association 
described in the observational literature4,5; however, using another instrument, such as 
rs700752, suggests a protective effect. Alternatively, assuming our results represent the 
effect of IGF-II on disease, they are in agreement with previous findings with respect to 
PSA-detected prostate cancer, although they found no evidence for an association of this 
biomarker with cancer grade4,5. 
 
Conclusions 
Using MR to establish the causal effects of a modifiable exposure, such as IGF levels, on 
an outcome of interest requires genetic variants that qualify as instruments for the 
exposure given a set of assumptions. Thus, it is important that strong instruments are 
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valid across populations, particularly as two-sample MR becomes more common. When 
phenotypes are known to vary significantly with population characteristics it would be 
desirable to make sure that they are being properly instrumented before engaging in an 
MR analysis. We have found evidence that the IGF axis contributes to some extent to 
prostate cancer progression to high grade cancer and mortality but the instruments 
currently available for circulating IGFs do not allow us to pinpoint which biomarker or 
biomarkers underlie the causal relationship.  
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Figure 1. Directed acyclic graph (DAG) showing the instrumental variable (IV) assumptions underpinning a Mendelian 
randomization analysis of circulating IGF levels with prostate cancer.  
 
IV models use associations A and B to estimate the causal effect of IGF on prostate cancer C (C = B/A). The instrument is assumed not to 
have a direct effect on the outcome, hence the dashed line is to illustrate that association B is required for IV estimation. The effect of 
genotype on the outcome should be mediated only through the intermediate phenotype (no pleiotropy). 
The numerator of the two sample IV estimator is the log odds ratio from a logistic regression of the outcome (Y) on the instrument (Z) in 
the PRACTICAL population and the denominator is the beta coefficient from a linear regression of the exposure (X) on the instrument 
(Z) in the ProtecT or UKHLS population or obtained from the literature.   
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Table 1. Clinical characteristics of prostate cancer cases in 25 PRACTICAL studies. N = 45,928 men. 
study country 
N 
controls 
N 
cases 
mean age at 
diagnosis 
(years) 
mean PSA at 
diagnosis 
(ng/ml) 
European 
ethnicity 
(%)a 
family 
history of 
prostate 
cancer (%)a,b 
high Gleason 
score (≥7, %)a 
advanced 
stage 
(%)a,c 
screen-
detected 
cancer 
(%)a 
CAPS Sweden 664 1153 66.1 79.6 100 17.4 49.9f 30.3 0.0 
CPCS1 Denmark 2756 848 69.5 48.0 99.6 8.2f 71.2f n/a 0.0 
CPCS2 Denmark 1001 265 64.9 36.0 99.4 14.7f 52.2f n/a 0.0 
EPIC Europe 1079 722 64.9 0.2 100 n/a 27.9f 4.0f 0.0 
EPIC-
Norfolk 
UK 911 481 72.1 n/a 99.9 2.5 39.4f n/a n/a 
ESTHER Germany 318 313 65.5 58.7 100 8.9f 48.0 27.6 61.9f 
FHCRC USA 729 761 59.7 16.1 99.9 21.7 41.7 20.2 n/a 
IPO-Porto Portugal 66 183 59.3 8.3 100 20.0f 84.2 64.5 82.8f 
MAYO USA 488 767 65.2 15.5 100 29.1 55.3f 45.5 73.7f 
MCCSd Australia 1169 1650 58.5 18.8 98.8 23.5f 53.4 14.5 n/a 
MEC USA 829 819 69.5 n/a 100 13.0 n/a 12.5 n/a 
MOFFITT USA 96 404 65.0 7.3 97.5 22.3 43.4 3.6 0.0f 
PCMUS Bulgaria 140 151 69.3 32.5 100 5.3 59.6 46.7 21.2 
Poland Poland 359 438 67.7 40.2 100 10.6 32.8f 37.1f 0.0f 
PPF-UNIS UK 187 244 68.9 32.1 99.8 25.3 45.2f 28.8f n/a 
ProMPT UK 2 166 66.3 33.0 100 34.6 74.3f 34.7 0.0f 
ProtecT UK 1458 1545 62.7 9.6 99.7 8.0f 29.9 11.4 100.0 
QLD Australia 85 139 61.4 7.4 99.1e 37.8 83.6 0.0f n/a 
SEARCH UK 1231 1354 63.1 53.2 100 16.3 56.9f 18.0f 36.7f 
STHM1 Sweden 2224 2006 66.2 n/a 100 20.2 45.5f 14.4f n/a 
TAMPERE Finland 2413 2754 68.2 69.2 100 n/a 43.8f 21.4 46.8 
UKGPCS UK 4132 3838 63.6 88.0 99.8 22.4f 50.5f 36.4f 28.0f 
ULM Germany 354 603 63.8 19.1 100 44.9 51.3f 40.5 n/a 
UTAH USA 245 440 62.6 n/a 100 51.4 n/a 17.2f n/a 
WUGS USA 0 948 60.8 6.1 95.8 42.6f 59.3 24.2 n/a 
38 
 
Information in the table is given for the subset of individuals whose ethnicity was “European” (except for the study’s European ethnicity 
percentage). 
aPercent of cases with data available. 
bFamily history of prostate cancer in a first degree relative. 
cT3 or T4 on TNM staging, or if not available, “regional” or “distant” on SEER staging. 
dMCCS includes Risk Factors for Prostate Cancer Study (RFPCS) and The Early Onset Prostate Cancer Study (EOPCS). 
eInformation missing for more than 10% of individuals. 
fInformation missing for more than 10% of patients. 
n/a not available
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Table 2. Association of published SNPs with IGF biomarkers in ProtecT controls. 
   ProtecT: effect on published biomarkers ProtecT: effect on other biomarkers 
SNP 
effect 
allele/non-
effect 
allelea 
published 
associations 
mean difference in 
IGF levels (ng/ml) per 
effect allele 
95% CI p-value 
other 
associations 
mean 
difference in 
IGF levels 
(ng/ml) per 
effect allele 
95% CI p-value F R2 (%) 
rs3770473 G/T IGF-I 1.06 (-8.77,10.89) 0.83       
  IGFBP-3 -43.89 (-225.24,137.47) 0.64       
rs300982 G/A IGFBP-3 -139.80 (-420.66, 141.05) 0.33       
rs4234798 T/G IGFBP-3 -49.51 (-165.48,66.45) 0.40       
rs7703713 A/G IGF-I -1.32 (-8.14,5.49) 0.70 IGFBP-2 -0.07 (-0.14,-0.001) 0.04 2.5 0.34 
rs2153960 A/G IGF-I 3.67 (-3.16,10.49) 0.29 IGFBP-2 0.07 (0.002,0.14) 0.04 3.6 0.50 
rs998075 G/A IGF-I 1.78 (-4.14,7.71) 0.56       
rs998074 C/T IGF-I 1.78 (-4.14,7.71) 0.56       
rs7780564 C/A IGF-I 4.35 (-1.46,10.15) 0.14       
rs10228265 A/G IGFBP-3 -11.25 (-126.51,104.00) 0.85 IGF-II 27.31 (-1.71,56.33) 0.07 3.8 0.52 
rs1908751 T/C IGF-I -0.40 (-6.98,6.18) 0.91       
rs2270628 C/T IGFBP-3 3.35 (-129.87,136.56) 0.96 IGF-II 34.97 (1.40,68.54) 0.04 4.9 0.68 
rs6670 T/A IGF-I -5.62 (-14.58,3.35) 0.22       
rs3110697 G/A IGFBP-3 -34.10 (-144.90,76.69) 0.55 IGF-II 55.26 (27.60,82.92) 9.64x10-5 14.3 1.94 
rs9282734 G/T IGFBP-3 360.75 (-574.69,1296.20) 0.45       
rs2471551 G/C IGFBP-3 7.96 (-128.43,144.34) 0.91 IGF-I 9.03 (-1.65,16.42) 0.02 5.6 0.76 
      IGF-II -44.24 (-78.55,-9.93) 0.01 6.0 0.82 
rs2132572 C/T IGFBP-3 -52.69 (-180.87,75.48) 0.42 IGF-II 35.09 (2.79,67.38) 0.03 4.3 0.59 
  IGF-I -4.32 (-11.30,2.65) 0.22       
rs2132571 C/T IGFBP-3 62.68 (-53.82,179.19) 0.29 IGF-II 55.35 (26.15,84.55) 2.14x10-4 11.6 1.58 
      IGF-I 6.79 (0.45,13.13) 0.04 4.0 0.54 
rs924140 T/C IGFBP-3 13.33 (-97.43,124.10) 0.81 IGF-II 76.49 (49.08,103.89) 5.92x10-8 26.0 3.47 
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rs1496499 G/T IGF-Ib 3.12 (-2.48,8.72) 0.27 IGF-II 77.18 (49.81,104.55) 4.35x10-8 26.3 3.52 
rs11977526 A/G IGFBP-3 83.98 (-31.18,199.14) 0.15 IGF-II 94.78 (66.48,123.09) 9.53x10-11 37.8 4.98 
  IGF-Ib 3.07 (-2.77,8.91) 0.30       
rs700752 G/C IGF-I 9.22 (3.19,15.24) 0.003     7.7 1.05 
  IGFBP-3 219.21 (108.61,329.81) 1.09x10-4     13.6 1.86 
rs1245541 G/A IGF-I -0.79 (-6.93,5.34) 0.80       
rs217727 A/G IGF2 14.65 (-20.09,49.39) 0.41 IGFBP-3 135.16 (-2.00,272.33) 0.053 2.0 0.28 
rs6214 T/C IGF-I 2.64 (-3.51,8.79) 0.40       
rs1520220 G/C IGF-I 6.37 (-1.88,14.61) 0.13       
rs5742694 A/C IGF-I -5.59 (-12.74,1.56) 0.13       
rs978458 T/C IGF-I 5.22 (-1.79,12.23) 0.14       
rs5742678 C/G IGF-I 5.22 (-1.79,12.23) 0.14       
rs972936 C/T IGF-I -5.22 (-12.23,1.79) 0.14       
rs2288378 T/C IGF-I 5.60 (-1.55,12.74) 0.12       
rs7136446 C/T IGF-I 3.81 (-2.19,9.81) 0.21       
rs10735380 G/A IGF-I 6.13 (-0.71,12.96) 0.08     3.4 0.47 
rs2195239 G/C IGF-I 5.89 (-1.35,13.13) 0.11       
rs12821878 G/A IGF-I 6.93 (-0.18,14.05) 0.06     3.2 0.43 
rs5742615 T/G IGF-I 3.99 (-28.62,36.60) 0.81       
rs2162679 T/C IGFBP-3 -38.78 (-201.52,123.96) 0.64       
rs5742612 G/A IGF-I -8.36 (-25.99,9.26) 0.35       
  IGFBP-3 -81.73 (-409.99,246.53) 0.63       
rs35767 A/G IGF-I 1.27 (-7.47,10.01) 0.78       
  IGFBP-3 38.78 (-123.96,201.52) 0.64       
rs35766 C/T IGF-I 3.58 (-4.85,12.02) 0.41       
rs35765 T/G IGF-I 6.45 (-3.14,16.04) 0.19       
rs7965399 C/T IGF-I -4.86 (-20.59,10.86) 0.54       
rs11111285 G/A IGF-I -4.96 (-20.73,10.80) 0.54       
  IGFBP-2 0.003 (-0.15,0.16) 0.97       
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rs855211 A/G IGF-I 2.50 (-5.75,10.75) 0.55       
rs10778177 C/T IGF-I -1.22 (-9.80,7.36) 0.78       
rs855203 C/A IGF-I 2.52 (-7.95,12.99) 0.64       
rs1457596 A/G IGF-I 2.94 (-7.83,13.71) 0.59       
rs7964748 A/G IGF-I 1.25 (-6.44,8.94) 0.75       
rs907806 G/A IGFBP-3 -112.72 (-285.09,59.66) 0.20       
rs213656 T/G IGF-I 4.32 (-1.66,10.30) 0.16 IGFBP-2 -0.06 (-0.12,0.00) 0.05 4.1 0.56 
rs3751830 C/T IGF-I 3.23 (-2.80,9.26) 0.29 IGFBP-2 -0.05 (-0.11,0.01) 0.09 3.3 0.44 
rs197056 A/G IGF-I 6.70 (0.61,12.78) 0.03 IGFBP-2 -0.06 (-0.12,0.00) 0.06 3.6 0.50 
rs174643 G/A IGF-I 4.24 (-1.64,10.11) 0.16 IGFBP-2 -0.05 (-0.11,0.01) 0.09 3.3 0.45 
rs1178436 C/T IGFBP-3 188.47 (45.27,331.67) 0.01     7.1 0.98 
rs1065656 G/C IGFBP-3 146.47 (27.31,265.63) 0.02     5.3 0.73 
rs17559 A/G IGFBP-3 100.90 (-74.95,276.75) 0.26       
rs11865665 G/A IGFBP-3 164.35 (-40.99,369.68) 0.12       
 
aThe effect allele is expected to increase the levels of biomarkers reported in the literature. 
bIGF-I adjusted for IGFBP-3. 
Circulating IGFBP-2 was natural log transformed.  
The regression models were adjusted for age and 10 principal components.  
IGF-I N=727, IGF-II N=718, IGFBP-2 N=724, IGFBP-3 N=712. 
In bold, SNPs uncovered in a GWAS of IGF-I and IGFBP-3 levels. 
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Table 3. SNPs associated with IGF levels in ProtecT and prostate cancer risk, grade and stage in the PRACTICAL consortium. 
SNP 
chromosome 
positiona 
effect/non-
effect 
alleleb 
OR case-
controlc 
95% CI p-value 
I2 
(%) 
OR 
Gleason 
graded 
95% CI 
p-
value 
I2 
(%) 
OR 
stagee 
95% CI p-value I2 (%) 
rs3110697 7:45915430 G/A 1.00 (0.97,1.04) 0.79 0.0 1.06 (0.98,1.14) 0.15f 55.3 1.03 (0.98,1.08) 0.26 32.4 
rs2854746 7:45921046 C/G 1.02 (0.99,1.05) 0.28 0.0 1.04 (0.99,1.08) 0.13 6.0 1.00 (0.93,1.08) 0.93f 39.7 
rs2854744 7:45921476 A/C 1.01 (0.98,1.05) 0.39 17.4 1.04 (1.00,1.09) 0.08 20.6 1.02 (0.96,1.07) 0.56 30.6 
rs2132571 7:45922075 C/T 1.00 (0.97,1.04) 0.88 28.7 1.03 (0.98,1.08) 0.26 0.0 1.00 (0.94,1.05) 0.85 0.0 
rs924140 7:45923515 T/C 1.01 (0.98,1.05) 0.37 30.6 1.04 (1.00,1.09) 0.08 19.0 1.02 (0.95,1.10) 0.63f 37.0 
rs1496499 7:45939424 G/T 1.01 (0.96,1.06) 0.69f 41.7 1.05 (1.01,1.10) 0.03 17.5 1.03 (0.98,1.08) 0.32 33.4 
rs11977526 7:45968511 A/G 1.01 (0.98,1.05) 0.41 16.3 1.05 (1.00,1.10) 0.06 11.8 1.04 (0.98,1.10) 0.17 33.3 
rs700752 7:46713955 G/C 1.00 (0.97,1.04) 0.85 0.0 0.97 (0.92,1.01) 0.17 0.0 0.97 (0.92,1.03) 0.30 0.0 
 
Fixed-effects and random-effects meta-analyses adjusted for age and 15 principal components. 
aGRCh38.p2. 
bThe effect allele is expected to increase the levels of biomarkers reported in the literature. 
c22 studies included. 
dGleason grade: <7 vs ≥7. 23 studies included. 
eStage: localised vs advanced. 21 studies included. 
fRandom effects meta-analysis. 
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19,071 cases/19,994 controls. 
9,429 low grade (<7)/8,913 high grade (≥7) disease. 
14,201 localised/4,455 advanced disease. 
